The molecular target: why TTR is uniquely tractable
Transthyretin amyloidosis (ATTR) is caused by a single protein — TTR — secreted predominantly by the liver, making hepatic TTR biosynthesis an unusually accessible intervention point for both gene-silencing and small-molecule approaches. TTR functions as a homo-tetramer, transporting retinol-binding protein/vitamin A and thyroxine (T4) in plasma and cerebrospinal fluid. The pathogenic mechanism is partial unfolding of the tetramer, generating monomeric intermediates that misfold and assemble into β-sheet-rich amyloid fibrils that deposit in the heart, peripheral nerves, and other tissues.
The disease exists in two primary subtypes. Hereditary ATTR (hATTR) is driven by autosomal dominant TTR gene mutations that destabilize the tetramer; more than 85 amyloidogenic variants have been identified, with V30M the most common and V122I carried by approximately 3.9% of the African American population. Wild-type ATTR (wtATTR, also termed senile systemic amyloidosis) arises from age-related misfolding of normal-sequence TTR and is estimated to affect more than 25% of individuals over 80 years of age — a figure that underscores the scale of the unmet need as global populations age.
Wild-type transthyretin amyloidosis (wtATTR), also known as senile systemic amyloidosis, is estimated to affect more than 25% of individuals over 80 years of age, making it one of the most prevalent forms of cardiac amyloidosis in elderly populations.
Clinical manifestations span familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (ATTR-CM), leptomeningeal and CNS amyloidosis, and ocular amyloidosis including vitreous amyloid deposits. More recent patent filings also extend TTR biology to Stargardt disease, age-related macular degeneration, and metabolic disorders including insulin resistance and type II diabetes — significantly broadening the addressable patient population beyond the classical cardiac and neurologic indications tracked by bodies such as WHO and NIH.
Beyond its transport functions, TTR also acts as a protease capable of cleaving apoA-I, amyloid β-peptide, and neuropeptide Y — a biological role that adds complexity to therapeutic targeting and may have implications for combination strategies that modulate TTR levels systemically.
RNA silencing dominates the ATTR patent landscape
RNA interference is the dominant therapeutic modality in the ATTR patent record, with Alnylam Pharmaceuticals holding the largest and most globally diversified portfolio across both approved platforms. The core mechanism is RISC-mediated cleavage of TTR mRNA in hepatocytes, reducing circulating TTR protein and consequently amyloid fibril formation. Two distinct delivery platforms have been prosecuted to clinical use.
Patisiran (LNP-formulated siRNA) is administered intravenously at 0.3 mg siRNA/kg body weight every three weeks using an LNP formulation containing DLin-MC3-DMA, DSPC, cholesterol, and PEG2000-C-DMG. Dose-response data cited in retrieved patent filings indicate the LNP formulation achieves approximately 85–90% reduction in TTR mRNA at 0.3 mg/kg, and approximately 50% reduction at 0.1 mg/kg. Clinical endpoints incorporated into patent text include mNIS+7, FAP stage, PND score, serum TTR concentration, and echocardiographic parameters, with serum TTR reduction targets of less than 50 µg/mL or at least 80% reduction from baseline.
Vutrisiran (AD-51547, GalNAc-conjugated siRNA) is administered subcutaneously at a fixed dose of approximately 25–50 mg, enabling self-administration via prefilled syringe or auto-injector. Retrieved filings describe highly modified nucleotide sequences incorporating 2′-O-methyl, 2′-fluoro, and phosphorothioate modifications for metabolic stability. The antisense strand target sequence disclosed across multiple Alnylam filings is 5′-UGGGAUUUCAUGUAACCAAGA-3′. Quality-of-life endpoint data (Norfolk QOL-DN score improvement) appear in retrieved Japanese filings, indicating clinical-stage data integration.
Alnylam’s patent activity in this dataset spans filing dates from 2008 provisional priority through 2026 pending applications, covering dsRNA composition claims, nucleotide modification patterns, LNP delivery, GalNAc conjugation, clinical dosing, neuropathy endpoint methods, and biomarker-based treatment monitoring across US, WO, EP, CA, AU, IL, JP, CN, KR, SG, MX, IN, CL, and BR jurisdictions.
Map the full TTR RNAi patent landscape — assignees, filing dates, and claim scope — in PatSnap Eureka.
Explore TTR Patent Data in PatSnap Eureka →A specialist sub-modality targets ocular amyloidosis: direct delivery of TTR-targeting dsRNA conjugated to cholesterol to the retinal pigment epithelium (RPE), addressing vitreous amyloid deposits as a distinct clinical manifestation of FAP. Kumamoto University and Alnylam both hold active Australian patents in this area. New entrants in the most recently dated filings include Amgen (GalNAc-siRNA targeting TTR mRNA for ATTR-CM, CN filing 2025), Shanghai Argo Biopharmaceutical (WO filing 2025 covering both dsRNA and antisense polynucleotide compositions), and Ruizheng Gene (Suzhou) (CN filing 2024 describing long-term TTR inhibition strategies).
Patisiran, the first approved RNA interference therapy for ATTR amyloidosis, is administered intravenously at 0.3 mg siRNA/kg body weight every three weeks and achieves approximately 85–90% reduction in hepatic TTR mRNA at that dose level, according to Alnylam Pharmaceuticals patent filings.
Antisense oligonucleotides (ASOs) represent a validated parallel modality: inotersen (and its enhanced version AKCEA-TTR-LRx) is referenced across multiple retrieved results as a co-treatment comparator and monitored via the same biomarker frameworks as RNAi agents. No dedicated ASO composition patents were retrieved as primary filings in this dataset, but the ASO class is confirmed as an established therapeutic option tracked by regulators including the FDA.
“The antisense strand target sequence 5′-UGGGAUUUCAUGUAACCAAGA-3′ is the most consistently disclosed guide sequence for RISC-mediated TTR mRNA cleavage across Alnylam’s patent families — a molecular fingerprint at the heart of the RNAi-TTR IP estate.”
Next-generation TTR stabilizers: moving beyond tafamidis
TTR tetramer stabilizers represent the second major modality in the ATTR pipeline. Tafamidis and diflunisal bind at the T4 hormone-binding sites of the TTR homo-tetramer, kinetically stabilizing the native tetramer against dissociation and thereby slowing amyloid fibril formation. However, multiple patent filings explicitly acknowledge that “symptoms continue to worsen on treatment in a large proportion of patients” on these agents — the therapeutic gap that next-generation compounds aim to close.
AG10 (acoramidis), developed by Eidos Therapeutics (now part of BridgeBio Pharma), is the subject of dedicated patent families describing specific dosing regimens for ATTR-CM patients. Retrieved filings describe clinical observations of increased serum TTR levels above baseline in subjects receiving AG10 for 28 days — a pharmacodynamic signal interpreted as evidence of tetramer stabilization reducing TTR clearance. The kinetic versus thermodynamic distinction in stabilization (as described in Columbia University filings, citing T119M and R104H protective mutations) provides the structural rationale for next-generation compound design.
Two structurally novel stabilizer approaches appear in the dataset. UCL Business Ltd discloses bivalent small-molecule TTR stabilizers with a general A-L-B scaffold designed to protect the native tetrameric form from proteolytic cleavage — a structurally distinct approach from existing T4-site binders. Rensselaer Polytechnic Institute describes a co-drug strategy combining a selective TTR ligand (which engages the RBP4-TTR complex to reduce retinol trafficking to the retina) with a C20-D3-modified retinoid, targeting both macular degeneration and TTR amyloidosis simultaneously in a single molecular entity.
Multiple patent filings acknowledge that symptoms continue to worsen on tafamidis or diflunisal treatment in a large proportion of ATTR patients — the therapeutic gap that drives development of next-generation stabilizers such as AG10 (acoramidis), bivalent UCL scaffolds, and the Rensselaer co-drug approach targeting the RBP4-TTR protein–protein interaction.
Monoclonal antibodies and CRISPR: clearing deposits and editing the gene
Anti-TTR monoclonal antibodies and CRISPR/Cas9 gene editing represent the two most mechanistically distinctive modalities in the current ATTR pipeline, targeting different points in the disease process — existing amyloid deposits and permanent hepatic gene expression, respectively.
Anti-TTR monoclonal antibodies
NeurImmune AG’s retrieved patent families describe anti-TTR antibodies (including NI006/ALXN2220) designed to selectively bind misfolded, monomeric, and aggregated TTR — not native tetramers — by targeting conformational epitopes exposed during misfolding. This mechanism of action is described as fundamentally different from stabilizers or RNA silencing: it aims at amyloid removal from tissues including the heart, rather than prevention of new deposition. Retrieved CN and JP filings describe dosing regimens for ATTR-CM adults treated with NI006/ALXN2220, indicating clinical-stage activity.
Prothena Biosciences Limited discloses anti-TTR antibodies including PRX004 and antibodies 9D5 and 18C5, which bind epitopes within residues 89–97 and 101–109 of TTR and preferentially recognize misfolded over native tetrameric TTR. Retrieved filings describe both therapeutic and diagnostic applications, including detection and monitoring of misfolded TTR in patient samples. A Phase II trial (NCT03044353) for an anti-SAP antibody approach was referenced in retrieved results as terminated early; Prothena’s antibodies are framed as improvements with a defined dosing strategy for the cardiac indication. Chemo-Sero-Therapeutic Research Institute (Kaketsuken) and Novo Nordisk also hold retrieved patents for human anti-TTR antibodies with defined CDR sequences that inhibit TTR fibrillization.
Anti-TTR monoclonal antibodies such as NI006/ALXN2220 (NeurImmune AG) selectively bind misfolded and aggregated TTR via conformational epitopes at residues 89–97 and 101–109 — epitopes that are cryptic in native tetramers — enabling selective targeting of pathogenic amyloid deposits for clearance rather than prevention of new deposition.
CRISPR/Cas9 in vivo gene editing
Intellia Therapeutics’ retrieved filing describes what it characterises as the first systemic administration of a CRISPR/Cas9-based therapeutic for in vivo editing in a clinical trial, specifically targeting the TTR gene in liver cells. The approach delivers an LNP composition containing mRNA encoding a Cas nuclease and a guide RNA targeting TTR, aiming for permanent reduction in hepatic TTR expression — a single-administration approach that, if proven durable, would challenge the repeat-dosing paradigm of current RNAi and ASO therapies.
Peptide inhibitors represent a further mechanistically distinct approach: the Regents of the University of California disclose peptides that bind specifically to aggregation-driving beta-sheet segments of TTR, blocking fibrillization and reducing cytotoxicity. These peptides, coupled to heterologous amino acid tags, target the aggregation interface rather than upstream gene expression, and appear preclinical in the retrieved dataset. Research standards for gene-editing therapeutics are actively being developed by bodies including ISO and scientific communities represented by Nature.
Track CRISPR TTR editing patents and anti-amyloid antibody IP in real time with PatSnap Eureka.
Analyse ATTR Pipeline IP in PatSnap Eureka →Combination strategies and emerging therapeutic directions
Combination approaches represent the most strategically complex zone in the current ATTR patent landscape, with mechanistically complementary pairings emerging across multiple assignees.
NeurImmune AG’s retrieved patent families (WO, IL, CA, AU, JP; priority from EP 2020) explicitly claim a combination therapy comprising an anti-TTR antibody (NI006/ALXN2220) and a TTR tetramer stabilizer (tafamidis or diflunisal). The rationale is mechanistically complementary: stabilizers prevent new fibril formation from circulating TTR, while antibodies target existing misfolded and aggregated TTR deposits for clearance. Shanghai Argo Biopharmaceutical’s 2025 WO filing explicitly envisions combining TTR dsRNA or ASO agents with other TTR-targeted therapeutics and non-TTR agents, signalling interest in sequential or concurrent multi-modality approaches.
Several emerging directions signal the next phase of ATTR innovation. Intellia Therapeutics’ CRISPR/Cas9 program, if proven durable, introduces a potential single-dose cure that would challenge the repeat-dosing economics of RNAi and ASO platforms. Rensselaer Polytechnic Institute’s 2024–2026 WO/AU filings signal an emerging concept of mechanistic dual-targeting — using TTR ligands that simultaneously stabilize tetramers and modulate retinol/RBP4 trafficking to address both ATTR and retinal degenerative disease in a single molecular entity. Extended indication filings for Stargardt disease, dry and wet AMD, diabetic retinopathy, and metabolic disorders further broaden the addressable patient population beyond the classical cardiac and neurologic core.
“NeurImmune’s anti-TTR antibody + stabilizer combination is mechanistically complementary by design: stabilizers prevent new fibril formation from circulating TTR, while antibodies target existing misfolded deposits for clearance — a dual-attack strategy that no single modality can replicate.”
IP strategy signals for ATTR drug developers
Alnylam Pharmaceuticals holds the largest and most globally diversified patent position on TTR-targeting RNA silencing in this dataset, covering both LNP (patisiran) and GalNAc (vutrisiran) delivery platforms across nearly every major jurisdiction. However, the appearance of Amgen and Shanghai Argo Biopharmaceutical filings in 2025 signals that freedom-to-operate analysis will become increasingly critical for new entrants, particularly around nucleotide modification patterns and delivery vehicle chemistry.
Combination therapy represents the most strategically complex IP zone. NeurImmune’s anti-TTR antibody + stabilizer combination patents and Alnylam’s ongoing TTR silencing combination disclosures create overlapping claim spaces. Drug developers pursuing combination regimens should perform landscape analysis against NeurImmune (IL, CA, AU, JP), Prothena, and Alnylam combination method claims before IND filing, as noted in the context of patent landscape tools available through platforms such as PatSnap.
Biomarker and diagnostic IP is a strategically underappreciated dimension. Alnylam’s filings disclose neurofilament light chain (NFL) as a validated pharmacodynamic biomarker for monitoring treatment response in TTR amyloidosis polyneuropathy, enabling patient selection and therapeutic assessment. Prothena’s antibodies 9D5 and 18C5 (binding epitopes 89–97 and 101–109) are described with detection and monitoring applications alongside therapeutic use — a pattern that could create ecosystem lock-in around specific monitoring platforms. Patent protection for companion diagnostics and biomarker-based treatment monitoring is an area where WIPO patent filing activity has accelerated across therapeutic areas.
Alnylam Pharmaceuticals’ ATTR-related patent activity spans filing dates from 2008 provisional priority through 2026 pending applications across US, WO, EP, CA, AU, IL, JP, CN, KR, SG, MX, IN, CL, and BR jurisdictions — one of the most geographically diversified RNA interference patent portfolios in the biopharmaceutical sector.
Ocular amyloidosis and expanded indication filings represent an underserved IP space. Dedicated patent filings for RPE-targeted siRNA, retinal delivery, Stargardt disease, and AMD from multiple organisations suggest a growing secondary market beyond the cardiac and neurologic core indications — presenting opportunities for regional biotech and ophthalmic-focused developers. The PatSnap life sciences platform provides tools for monitoring these emerging filing clusters in real time.